Product image of Norigon (Butamirate Citrate) supplied by GNH India

Norigon

Active Ingredient:
Butamirate Citrate
Origin:
EU

Norigon (Butamirate Citrate)

Butamirate citrate, the active ingredient in Norigon, is a cough suppressant presented as an oral tablet for systemic use. It is indicated for the relief of dry, non‑productive coughs in adults and adolescents and provides symptomatic control without affecting normal respiratory function.

GNH India supplies Norigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and other markets. We partner with accredited manufacturers to maintain product integrity throughout the supply chain.

Manufacturer / TM Owner

Extractumpharma Co.Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Butamirate citrate is used as an antitussive agent to suppress cough reflexes in the respiratory tract.

  • Dry cough: reduces frequency and intensity of coughing episodes.
  • Non‑productive cough: provides symptomatic relief without producing sputum.
  • Irritative cough due to throat irritation: alleviates cough caused by mild upper‑respiratory irritation.
  • Cough during night: helps maintain uninterrupted sleep.
  • Cough after exposure to dry air: eases discomfort.

How It Works

  • Butamirate citrate acts centrally by modulating the cough centre in the medulla oblongata. Although its exact receptor interaction is not fully defined, the compound is thought to depress the neuronal activity that triggers the cough reflex, thereby reducing the urge to cough without significant peripheral bronchodilation. The effect is achieved after oral absorption, with peak plasma concentrations reached within one hour, and the drug is eliminated primarily via renal excretion.

Side Effects

Butamirate citrate may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Drowsiness: mild sedation or feeling of tiredness.
  • Nausea: occasional upset stomach.
  • Dry mouth: reduced salivation.
  • Dizziness: light‑headed sensation.

Serious or Rare Side Effects

  • Allergic reaction: rash, itching, swelling, or difficulty breathing.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Anaphylaxis: life‑threatening systemic allergic response.

Precautions & Warnings

When using Norigon, several precautions should be observed to ensure safe and effective therapy.

  • Assess patient history: confirm absence of hypersensitivity to butamirate or similar agents.
  • Use in pregnancy: avoid unless clearly needed, as safety data are limited.
  • Use in lactation: caution advised; limited information on excretion in breast milk.
  • Concomitant CNS depressants: monitor for additive sedation.
  • Renal impairment: dose adjustment may be required; monitor renal function.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Avoid Interactions

Butamirate citrate can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Alcohol: may enhance central nervous system depression and drowsiness.
  • Opioid antitussives (e.g., codeine): combined use can increase risk of respiratory depression.

Moderate Interactions (Monitor Closely)

  • Sedative antihistamines: may potentiate drowsiness.
  • CNS depressants (benzodiazepines, barbiturates): monitor for excessive sedation.
  • Anticholinergic drugs: may worsen dry mouth.
  • Antihypertensive agents: possible additive hypotensive effect.

Frequently Asked Questions

Norigon contains butamirate citrate and is used as an over‑the‑counter antitussive to relieve dry, non‑productive coughs. It helps reduce the frequency and intensity of coughing episodes, providing symptomatic comfort for patients with irritative or nocturnal coughs.

Butamirate citrate acts on the central cough centre located in the medulla. By depressing neuronal activity that initiates the cough reflex, it lowers the urge to cough without causing bronchodilation. The exact receptor binding is not fully clarified, but the overall effect is a reduction in cough frequency.

The appropriate dose of Norigon is determined by a qualified healthcare professional based on the individual’s age, weight, and clinical condition. Patients should follow the prescriber’s instructions and the product label; no standard dosing regimen is provided here.

Safety data for butamirate citrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a healthcare provider.

To order Norigon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Norigon (butamirate citrate) is a non‑opioid antitussive that works centrally without the analgesic or constipation risks associated with codeine. It is generally considered safer for short‑term use and is available over the counter, whereas codeine requires prescription and carries a higher potential for dependence.

Norigon should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Norigon is taken orally, typically as a tablet, with or without a small amount of water. It should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse reactions, although rare, include allergic responses such as rash, swelling, difficulty breathing, hepatic dysfunction indicated by jaundice or elevated liver enzymes, and anaphylaxis. Patients experiencing any of these symptoms should seek immediate medical attention.

Norigon should be avoided in individuals with known hypersensitivity to butamirate citrate or any of its excipients, in patients with severe hepatic impairment, and in those taking other central nervous system depressants where additive sedation could be hazardous. Pregnant or breastfeeding women should use it only under medical advice.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Butamirate Citrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT